The EMN 2027 program is designed to address the most critical questions in multiple myeloma today. We will focus on current diagnostic and clinical challenges, cutting-edge biology, novel treatments, practical guidelines, with a careful look at future directions and innovations. We anticipate lively discussions on topics such as: · Novel treatments and their sequencing in newly diagnosed (NDMM) and relapsed/refractory (RRMM) disease · Minimal Residual Disease (MRD) and its role in evaluating treatment efficacy · The future of myeloma research, including the role of AI in trial design and the clinical and economic implications of new therapies · Best approach for High-Risk patients · Lively debates with experts in the field coming from all over Europe and beyond